Quick context
Bremelanotide
影响中枢黑皮质素信号；获批用途仅限于特定处方适应证。
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Back to all 64 profiles
Approved medicine特定用途获批
Community protocol · Bremelanotide
Bremelanotide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: PT-141 · Vyleesi
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Approved medicine
Approved uses exist, but dose, formulation, device and monitoring are product- and indication-specific. A community table cannot replace the prescribing information or a prescription.
Amount status
Only the prescribing information for the exact approved product applies; brands, concentrations and indications are not interchangeable.
Profile evidence level: established.
Timing
Intervals, time of day and missed-dose handling depend on the product and indication.
No individual recommendation.
Cycle/duration
Approved medicines are clinician-managed treatment, not freely designed community cycles.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
No generic calculator
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
For approved finished products, only the relevant prescribing information, original concentration and intended delivery system apply. Prefilled pens, syringes or product-specific vials must not be converted with a generic U-100 table.
Mechanism and research questions
Melanocortin receptor agonist
Bremelanotide is classified as “Melanocortin receptor agonist”. 影响中枢黑皮质素信号；获批用途仅限于特定处方适应证。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
黑皮质素受体激活
这项研究考察激活黑皮质素受体如何影响色素沉着或性唤起信号,如同根据受体亚型控制不同身体功能的开关。研究中测量皮肤色素沉着或生理唤起标志物。
生殖激素信号传导
这项研究考察对影响性欲、周期或生育能力的激素轴的作用,类似于连接多个腺体的反馈回路。研究中测量激素水平和主观问卷调查结果。
神经内分泌信号传导
这项研究考察神经系统与激素分泌腺体之间如何相互沟通,类似于连接大脑与远端器官的双向电话线路。研究人员通常同时测量血液中的激素水平和神经系统活动标志物。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
生育与性欲论坛
人们讨论与性欲或月经周期相关的激素信号肽的个人经历,常与已获批产品进行比较。这类经验分享是个体化的,无法替代医学评估或对照研究。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
综合健康论坛
人们在此交流使用各类产品后情绪、睡眠和整体感受等更宽泛的健康印象,通常没有结构化的记录。这类笼统印象无法替代有针对性的临床检查。
Adverse effects and risk boundaries
- 黑皮质素作用可引起恶心、潮红、血压变化、头痛、不希望的色素沉着及性方面不良反应；非选择性类似物不确定性更大。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 非典型痣/皮肤癌风险、未控制高血压、心血管疾病、阴茎异常勃起风险及妊娠均需医学评估。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 根据获批用途，可评估皮肤、血压、恶心、色素变化及适应证相关终点。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
证据充分
该批准仅适用于经过具体研究的用途。
Published evidence
所述生物学作用已有充分依据,或针对明确产品和用途已有经监管机构审查的大量人体数据。这些结论不能自动套用于其他产品或用途。
溴美拉肽已获批用于特定处方用途,不同于未获批准的Melanotan II。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
特定用途获批
在至少一个司法辖区作为特定适应证的处方活性成分；本网站不提供该产品。
WADA 2026
The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: approved drug product list
- Primary/technical sourceDailyMed — VYLEESI prescribing information
- Community referenceBremelanotide — Peptide Dosing Protocols